MUC18-Targeted ADC

Business

Study Reveals AMT-253 as a Potential First-in-Class ADC for Targeting Melanoma and Solid Tumors

The introduction of BRAF inhibitors and immune checkpoint inhibitors (ICIs) has substantially improved outcomes for melanoma patients. However, certain melanoma…

Read More »
Back to top button